ECSP099413A - COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO - Google Patents
COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEOInfo
- Publication number
- ECSP099413A ECSP099413A EC2009009413A ECSP099413A ECSP099413A EC SP099413 A ECSP099413 A EC SP099413A EC 2009009413 A EC2009009413 A EC 2009009413A EC SP099413 A ECSP099413 A EC SP099413A EC SP099413 A ECSP099413 A EC SP099413A
- Authority
- EC
- Ecuador
- Prior art keywords
- methods
- phenylethoxy
- trifluoro
- pyrimidine
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
Abstract
Se revelan los compuestos de la fórmula I, al igual que composiciones que los comprenden y métodos para utilizarlos en el tratamiento, la prevención y/o el manejo de trastornos y enfermedades. I
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87459606P | 2006-12-12 | 2006-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099413A true ECSP099413A (es) | 2009-07-31 |
Family
ID=39432875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009413A ECSP099413A (es) | 2006-12-12 | 2009-06-12 | COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO |
Country Status (25)
Country | Link |
---|---|
US (4) | US7553840B2 (es) |
EP (4) | EP2589600B1 (es) |
JP (1) | JP5361734B2 (es) |
KR (1) | KR101464391B1 (es) |
AR (1) | AR064279A1 (es) |
AU (1) | AU2007333120B2 (es) |
BR (1) | BRPI0720270B8 (es) |
CA (1) | CA2672233C (es) |
CO (1) | CO6220855A2 (es) |
DK (2) | DK2091940T6 (es) |
EA (1) | EA018150B1 (es) |
EC (1) | ECSP099413A (es) |
ES (3) | ES2625083T3 (es) |
HU (3) | HUE027896T2 (es) |
IL (2) | IL198806A (es) |
MX (1) | MX2009006195A (es) |
NL (1) | NL300929I2 (es) |
NO (2) | NO345062B1 (es) |
NZ (1) | NZ577004A (es) |
PL (2) | PL2091940T6 (es) |
PT (2) | PT3176159T (es) |
TW (1) | TWI412365B (es) |
UA (1) | UA99270C2 (es) |
WO (1) | WO2008073933A2 (es) |
ZA (1) | ZA200903367B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897763B2 (en) * | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US7855291B2 (en) * | 2005-12-29 | 2010-12-21 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
CN103265495B (zh) * | 2005-12-29 | 2016-11-16 | 莱西肯医药有限公司 | 多环氨基酸衍生物及其使用方法 |
UA99270C2 (en) * | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
KR20100037047A (ko) * | 2007-06-26 | 2010-04-08 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 세로토닌-매개 질환 및 장애의 치료 방법 |
US8093291B2 (en) * | 2007-06-26 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | Methods of using and compositions comprising tryptophan hydroxylase inhibitors |
EP2170397A1 (en) * | 2007-07-11 | 2010-04-07 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
US20090029993A1 (en) * | 2007-07-26 | 2009-01-29 | Qingyun Liu | Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein |
NZ583017A (en) * | 2007-08-24 | 2012-02-24 | Lexicon Pharmaceuticals Inc | Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
TWI439457B (zh) * | 2007-09-28 | 2014-06-01 | Lexicon Pharmaceuticals Inc | (s)-2-胺基-3-(4-(2-胺基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧)-嘧啶-4-基)苯基)丙酸乙酯之固體形式與其使用方法 |
TW200932729A (en) * | 2007-10-08 | 2009-08-01 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
JP2011516486A (ja) * | 2008-03-31 | 2011-05-26 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 骨質量疾患の診断、予防、及び治療方法 |
WO2010047712A1 (en) * | 2008-10-24 | 2010-04-29 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US8614222B2 (en) | 2008-11-13 | 2013-12-24 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating low bone mass diseases |
WO2010065333A1 (en) * | 2008-12-01 | 2010-06-10 | Lexicon Pharmaceuticals, Inc. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis |
WO2011053977A1 (en) | 2009-11-02 | 2011-05-05 | The Trustees Of Columbia University In The City Of New York | Compounds and methods for inhibiting serotonin synthesis |
CN102711749A (zh) | 2009-11-05 | 2012-10-03 | 莱西肯医药有限公司 | 用于癌症治疗的色氨酸羟化酶抑制剂 |
AU2010321979A1 (en) | 2009-11-19 | 2012-05-24 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US20120077831A1 (en) * | 2009-11-23 | 2012-03-29 | Philip Manton Brown | Methods and assays for the treatment of irritable bowel syndrome |
EP2504008A1 (en) * | 2009-11-23 | 2012-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and assays for the treatment of irritable bowel syndrome |
US20130137635A1 (en) * | 2010-02-10 | 2013-05-30 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease |
US20130116445A1 (en) * | 2010-07-12 | 2013-05-09 | Colorado State University Research Foundation | Triazolium carbene catalysts and processes for asymmetric carbon-carbon bond formation |
US20130338176A1 (en) * | 2010-10-29 | 2013-12-19 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating hyperlipidemia or atherosclerosis |
TW201245183A (en) | 2010-11-05 | 2012-11-16 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid |
JP2012156602A (ja) * | 2011-01-21 | 2012-08-16 | Ricoh Co Ltd | 情報処理装置、通信制御方法、及び通信制御システム |
KR101682417B1 (ko) * | 2011-02-25 | 2016-12-06 | 주식회사유한양행 | 다이아미노피리미딘 유도체 및 그의 제조방법 |
PT2753306T (pt) * | 2011-10-17 | 2020-11-11 | Lexicon Pharmaceuticals Inc | Formas de dosagem sólidas de 2-amino-3-(4-(2-amino-6-((r)-1- (4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2- trifluoroetoxi)pirimidin-4-il)fenil)propanoato de (s)-etilo |
WO2013148978A1 (en) * | 2012-03-30 | 2013-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for the treatment of necrotizing enterocolitis |
WO2014195847A2 (en) | 2013-06-03 | 2014-12-11 | Actelion Pharmaceuticals Ltd | Novel use of stable isotope labeled l-tryptophan |
UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
AR098436A1 (es) * | 2013-11-19 | 2016-05-26 | Actelion Pharmaceuticals Ltd | Compuestos tricíclicos de piperidina |
TW201609721A (zh) | 2013-11-19 | 2016-03-16 | 艾克泰聯製藥有限公司 | 三環咪唑化合物 |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
CA2980100A1 (en) | 2015-05-04 | 2016-11-10 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
WO2018060949A1 (en) | 2016-09-30 | 2018-04-05 | Roivant Sciences Gmbh | Tryptophan hydroxylase inhibitors for use in the treatment of liver diseases |
IL302529A (en) | 2018-03-08 | 2023-07-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
CN109020958A (zh) * | 2018-08-28 | 2018-12-18 | 湖南华腾制药有限公司 | 一种氘代色氨酸羟化酶抑制剂 |
CN109180650A (zh) * | 2018-08-28 | 2019-01-11 | 湖南华腾制药有限公司 | 一种氘代色氨酸羟化酶抑制剂的晶型 |
WO2023192003A1 (en) | 2022-04-01 | 2023-10-05 | Tersera Therapeutics Llc | Methods of reducing the likelihood of carcinoid heart disease in patients with neuroendocrine tumors |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US5958957A (en) | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
US6431478B1 (en) | 1999-06-01 | 2002-08-13 | Elan Pharma International Limited | Small-scale mill and method thereof |
WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
DE10112768A1 (de) | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
AU2002312230A1 (en) | 2001-06-05 | 2002-12-16 | Elan Pharma International Limited | System and method for milling materials |
US6976647B2 (en) | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
JP4002502B2 (ja) * | 2001-11-27 | 2007-11-07 | 三星電子株式会社 | 座標インタポレータの符号化/復号化装置及びその方法 |
US7713551B2 (en) | 2002-09-11 | 2010-05-11 | Elan Pharma International Ltd. | Gel stabilized nanoparticulate active agent compositions |
WO2004080943A1 (ja) | 2003-03-11 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤 |
US20050187266A1 (en) | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
US20050234066A1 (en) | 2004-04-15 | 2005-10-20 | Agouron Pharmaceuticals, Inc. | Alpha substituted carboxylic acids |
AU2004247013B2 (en) | 2003-05-14 | 2010-07-08 | Neurogenetic Pharmaceuticals, Inc. | Compounds and uses thereof in modulating amyloid beta |
US20050042177A1 (en) | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
US7377637B2 (en) * | 2005-10-11 | 2008-05-27 | Synergeyes, Inc. | Hybrid contact lens system and method of fitting |
CN103265495B (zh) * | 2005-12-29 | 2016-11-16 | 莱西肯医药有限公司 | 多环氨基酸衍生物及其使用方法 |
UA99270C2 (en) * | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
NZ583017A (en) * | 2007-08-24 | 2012-02-24 | Lexicon Pharmaceuticals Inc | Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
TWI439457B (zh) * | 2007-09-28 | 2014-06-01 | Lexicon Pharmaceuticals Inc | (s)-2-胺基-3-(4-(2-胺基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧)-嘧啶-4-基)苯基)丙酸乙酯之固體形式與其使用方法 |
-
2007
- 2007-11-12 UA UAA200907262A patent/UA99270C2/uk unknown
- 2007-12-10 TW TW096147104A patent/TWI412365B/zh active
- 2007-12-11 EP EP13153803.5A patent/EP2589600B1/en active Active
- 2007-12-11 PL PL07865487T patent/PL2091940T6/pl unknown
- 2007-12-11 PT PT162064935T patent/PT3176159T/pt unknown
- 2007-12-11 KR KR1020097012100A patent/KR101464391B1/ko active IP Right Grant
- 2007-12-11 EP EP07865487.8A patent/EP2091940B3/en active Active
- 2007-12-11 EA EA200970575A patent/EA018150B1/ru not_active IP Right Cessation
- 2007-12-11 AU AU2007333120A patent/AU2007333120B2/en active Active
- 2007-12-11 ES ES13153803.5T patent/ES2625083T3/es active Active
- 2007-12-11 JP JP2009541514A patent/JP5361734B2/ja active Active
- 2007-12-11 MX MX2009006195A patent/MX2009006195A/es active IP Right Grant
- 2007-12-11 PT PT78654878T patent/PT2091940E/pt unknown
- 2007-12-11 NZ NZ577004A patent/NZ577004A/en unknown
- 2007-12-11 EP EP16206493.5A patent/EP3176159B1/en active Active
- 2007-12-11 AR ARP070105537A patent/AR064279A1/es active IP Right Grant
- 2007-12-11 CA CA2672233A patent/CA2672233C/en not_active Expired - Fee Related
- 2007-12-11 PL PL16206493T patent/PL3176159T3/pl unknown
- 2007-12-11 ES ES07865487.8T patent/ES2562775T7/es active Active
- 2007-12-11 ES ES16206493T patent/ES2856871T3/es active Active
- 2007-12-11 HU HUE07865487A patent/HUE027896T2/en unknown
- 2007-12-11 WO PCT/US2007/087068 patent/WO2008073933A2/en active Application Filing
- 2007-12-11 BR BRPI0720270A patent/BRPI0720270B8/pt active IP Right Grant
- 2007-12-11 ZA ZA200903367A patent/ZA200903367B/xx unknown
- 2007-12-11 DK DK07865487.8T patent/DK2091940T6/en active
- 2007-12-11 HU HUE16206493A patent/HUE053098T2/hu unknown
- 2007-12-11 EP EP20191197.1A patent/EP3808740A1/en not_active Withdrawn
- 2007-12-11 DK DK16206493.5T patent/DK3176159T3/da active
- 2007-12-11 US US11/954,000 patent/US7553840B2/en active Active
-
2009
- 2009-05-19 IL IL198806A patent/IL198806A/en active IP Right Grant
- 2009-05-20 US US12/468,974 patent/US7709493B2/en active Active
- 2009-06-12 CO CO09061621A patent/CO6220855A2/es not_active Application Discontinuation
- 2009-06-12 EC EC2009009413A patent/ECSP099413A/es unknown
- 2009-07-10 NO NO20092639A patent/NO345062B1/no active Protection Beyond IP Right Term
-
2010
- 2010-04-05 US US12/754,341 patent/US7968559B2/en active Active
-
2011
- 2011-06-17 US US13/162,989 patent/US8772482B2/en active Active
-
2014
- 2014-10-23 IL IL235288A patent/IL235288A/en active IP Right Grant
-
2018
- 2018-02-14 NL NL300929C patent/NL300929I2/nl unknown
- 2018-02-19 HU HUS1800010C patent/HUS1800010I1/hu unknown
-
2021
- 2021-03-01 NO NO2021010C patent/NO2021010I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099413A (es) | COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO | |
PT1984357E (pt) | Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes | |
ECSP088210A (es) | Bencimidazoles sustituidos y métodos de preparación | |
EA200802213A1 (ru) | Способы лечения заболеваний крови | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
ECSP10010310A (es) | Nuevos compuestos y composiciones y métodos de uso | |
DK2089369T3 (da) | 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme | |
CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
ECSP066717A (es) | Compuestos de quinolina sustituidos | |
UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
ATE471324T1 (de) | Triazolophthalazine | |
UY27872A1 (es) | Inhibidores de caspasa y usos de los mismos. | |
DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
DOP2009000165A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
RS50629B (sr) | Amidni prolek gemcitabina, kompozicije i njihova primena | |
CL2007002384A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis. | |
UY30627A1 (es) | Inhibidores de metaloproteasas derivados de heterociclos | |
UY30520A1 (es) | Compuestos de pirimidina | |
TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
UA106880C2 (uk) | Нові гербіциди | |
EA200801365A1 (ru) | Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины | |
EA200801366A1 (ru) | Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина |